149 related articles for article (PubMed ID: 36980518)
1. Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses.
Messori A; Damuzzo V; Rivano M; Cancanelli L; Di Spazio L; Ossato A; Chiumente M; Mengato D
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980518
[TBL] [Abstract][Full Text] [Related]
2. A Comparison of Statistical Analysis Between "Real" Patients Reported in Kaplan-Meier Curves and "Reconstructed" Patients Estimated Through the IPDfromKM Method: Analysis of Eight Trials Evaluating Catheter Ablation of Ventricular Tachycardia.
Messori A; Fadda V; Romeo MR; Veneziano S; Trippoli S
Cureus; 2023 Oct; 15(10):e47891. PubMed ID: 37905162
[TBL] [Abstract][Full Text] [Related]
3. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves.
Liu N; Zhou Y; Lee JJ
BMC Med Res Methodol; 2021 Jun; 21(1):111. PubMed ID: 34074267
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data.
Ossato A; Damuzzo V; Baldo P; Mengato D; Chiumente M; Messori A
Cancer Med; 2023 Feb; 12(3):2155-2165. PubMed ID: 35920297
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method.
Trippoli S; Di Spazio L; Chiumente M; Messori A
Cureus; 2022 Feb; 14(2):e22645. PubMed ID: 35237496
[TBL] [Abstract][Full Text] [Related]
7. Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons.
Rivano M; Mengato D; Chiumente M; Messori A
Hematol Rep; 2023 Nov; 15(4):670-683. PubMed ID: 38132276
[TBL] [Abstract][Full Text] [Related]
8. The "One-to-Many" Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma.
Messori A; Rivano M; Cancanelli L; Damuzzo V; Ossato A; Chiumente M; Mengato D
Cureus; 2022 Aug; 14(8):e28369. PubMed ID: 36171827
[TBL] [Abstract][Full Text] [Related]
9. Long-term progression-free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons.
Messori A
Eur J Haematol; 2023 Jan; 110(1):60-66. PubMed ID: 36193009
[TBL] [Abstract][Full Text] [Related]
10. [Application of artificial intelligence for an early comparison of efficacy between new cancer drugs.].
Damuzzo V; Rivano M; Baldo P; Cancanelli L; Di Spazio L; Ossato A; Chiumente M; Messori A; Mengato D
Recenti Prog Med; 2022 Nov; 113(11):680-687. PubMed ID: 36318172
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. Synthetizing Published Evidence on Survival by Reconstruction of Patient-Level Data and Generation of a Multi-Trial Kaplan-Meier Curve.
Messori A
Cureus; 2021 Nov; 13(11):e19422. PubMed ID: 34786276
[TBL] [Abstract][Full Text] [Related]
13. Lutetium in prostate cancer: Reconstruction of patient-level data from published trials and generation of a multi-trial Kaplan-Meier curve.
Messori A
World J Methodol; 2022 May; 12(3):107-112. PubMed ID: 35721242
[TBL] [Abstract][Full Text] [Related]
14. Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials.
Rivano M; Cancanelli L; Di Spazio L; Mengato D; Chiumente M; Messori A
World J Urol; 2022 Nov; 40(11):2609-2615. PubMed ID: 36083316
[TBL] [Abstract][Full Text] [Related]
15. Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments.
Cancanelli L; Rivano M; Di Spazio L; Chiumente M; Mengato D; Messori A
Hematol Rep; 2023 Jan; 15(1):57-65. PubMed ID: 36648884
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall Survival Based on Reconstructed Patient-Level Data.
Messori A; Chiumente M; Mengato D
Clin Ther; 2022 Dec; 44(12):1626-1632. PubMed ID: 36503735
[TBL] [Abstract][Full Text] [Related]
17. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.
Messori A; Rivano M; Mengato D; Chiumente M
Cureus; 2022 Dec; 14(12):e33169. PubMed ID: 36726938
[TBL] [Abstract][Full Text] [Related]
18. Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents.
Messori A; Caccese E
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4666-4670. PubMed ID: 35856357
[TBL] [Abstract][Full Text] [Related]
19. Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group.
Everest L; Blommaert S; Tu D; Pater JL; Hay A; Cheung MC; Chan KKW
Value Health; 2022 Jul; 25(7):1157-1164. PubMed ID: 35779942
[TBL] [Abstract][Full Text] [Related]
20. IPDmada: An R Shiny tool for analyzing and visualizing individual patient data meta-analyses of diagnostic test accuracy.
Wang J; Keusters WR; Wen L; Leeflang MMG
Res Synth Methods; 2021 Jan; 12(1):45-54. PubMed ID: 32808437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
